Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study (MCH-ART)
|First Received Date ICMJE||August 22, 2013|
|Last Updated Date||July 5, 2016|
|Start Date ICMJE||March 2013|
|Primary Completion Date||July 2016 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Combined endpoint of (i) maternal HIV viral suppression, and (ii) maternal retention in ART services, at 12 months postpartum [ Time Frame: Up to one year post partum follow-up for all phase 3 participants ]|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT01933477 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE
||Subgroup analyses of the primary outcome according to participant demographic characteristics, medical history, clinical characteristics and psychosocial characteristics [ Time Frame: up to 12 months postpartum ]|
|Original Other Outcome Measures ICMJE||Same as current|
|Brief Title ICMJE||Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study|
|Official Title ICMJE||Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study|
|Brief Summary||The purpose of this study is to understand how to improve health care services for HIV-positive women during their pregnancy and after delivery. The study's aim is to compare two different ways of providing antiretroviral therapy for pregnant women with HIV. The study is to be conducted at the Gugulethu Midwife Obstetric Unit (MOU) in Cape Town. There are three phases of the study: Phase 1 is a cross-sectional evaluation of consecutive HIV-infected pregnant women attending their first antenatal clinic visit (n=1600); Phase 2 is an observational cohort that will follow women from Phase 1 who are eligible for ART (n=600) from the second antenatal clinic visit until the first postpartum visit; Phase 3 is a randomized trial of women from Phase 2 who are breastfeeding and will compare two different service models for delivering ART to women after they delivery their babies (n=480). For Phase 3, women who are taking ART will randomly be assigned to either (1) referral to receive ART at the nearest adult clinic at 4-8 weeks after delivery (this is currently how all women receive care in this setting) or (2) to continue to come to the antenatal clinic for ART services until the end of breastfeeding. All women will received the standard local ART services (with identical medications and medical treatment); they are different because some women will stay longer in care at the antenatal clinic. All women participating in Phase 3 will be followed through at least 2 months after they deliver.|
This study includes a three-phase design in which HIV-positive pregnant women are followed during the antenatal and postnatal periods. Throughout, participants will attend study measurement visits conducted separately from routine ART service appointments.
Phase 1 is a cross-sectional evaluation of consecutive HIV-infected pregnant women attending their first antenatal clinic visit seeking care at the study clinic. This phase of the study will allow characterization of the health status of the population of HIV-positive pregnant women seeking care at the Gugulethu (Midwife Obstetric Unit)MOU and the services they receive. At their first antenatal clinic visit, women will be approached to complete Informed Consent #1, including consent for abstraction of routine clinic data on obstetric and HIV-related care. As part of this cross-sectional study, participating women will complete a short questionnaire and undergo phlebotomy.
Phase 2 of the study is an observational cohort of all women who are eligible for initiation of lifelong antiretroviral therapy (following SA guidelines), from their second antenatal clinic visit until their first postpartum clinic visit (conducted within 7 days postpartum). This phase of the study will provide detailed description of ART initiation and antenatal follow-up in the population of women who will be involved in the postnatal component of the study, and be used to measure potential predictors of the primary outcome. At the second antenatal clinic visit, women from Phase 1 who are ART-eligible or who initiated ART during the pregnancy will be approached to complete Informed Consent #2, be interviewed with questionnaire on behavioral and psychosocial measures, and undergo phlebotomy. Women will complete another study measurement visit during the third trimester and again within 1 week postpartum (with study measurement visits timed to coincide with routine care appointments). At these visits, additional questionnaires and phlebotomy will be used to collect study measures.
Phase 3 of the study is a randomised trial of strategies for delivering ART to women during the postpartum period (the primary objective) with measurement of secondary outcomes during the postnatal period. Women enrolled in Phase 2 who are breastfeeding their infants will be approached to participate in the trial at the routine postpartum clinic visit (this takes place within 7 days of birth and is the only standard postpartum care for women). After completing Informed Consent #3, women will be interviewed with behavioral and psychosocial questionnaires and undergo phlebotomy for study measurements before randomization.
Randomization will be to one of two approaches to providing ART during the postpartum period to HIV-infected mothers who are breastfeeding:
Women randomized to Arm A or Arm B will be asked to return for four additional study visits during the postpartum period at approximately 6 weeks, 6 months, 9 months and 12 months postpartum. Details of study measurement visits conducted in both the antenatal and postnatal periods are described below in Section 8.
For women enrolled in Phases 1 and 2 of the study, participation will not impact on any aspect of routine antenatal and obstetric care during pregnancy. Similarly, throughout the antenatal period women's HIV-related care (including PMTCT services and ART) will not be affected in any way by participation, with ART initiated according to the current standard of care. For women enrolled in Phase 3 of the study, participation will only impact on the setting and approach to providing ART services to mothers during the postpartum period, comparing immediate referral to general adult ART services versus ongoing care in MCH-focused ART services within the Gugulethu MOU.
Overall, a total of approximately 1600 HIV+ pregnant women will participate in Phase 1 of the study over 12 months. From this group, it is anticipated that approximately 400-500 HIV+ pregnant women eligible for ART will be identified as eligible for Phase 2 participation. We estimate that of the approximately 600 women on ART followed in Phase 2, approximately 480 will be eligible for and enrolled into Phase 3 and randomized to one of two postpartum ART delivery strategies.
Follow-up of all participants in Phase 3 will end at 12 months postpartum. The total length of participation will vary based on gestational age at enrollment into Phase 2, ranging from a minimum of approximately 52 weeks to a maximum of approximately 80 weeks.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
|Intervention ICMJE||Other: MCH-focused ART services
Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Active, not recruiting|
|Estimated Completion Date||March 2017|
|Primary Completion Date||July 2016 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
Phase 2: Subset of Phase 1 participants who are ART-eligible
Phase 3: Subset of Phase 2 participants eligible for randomization
Individuals meeting any of the following exclusion criteria at the point in the study will be excluded:
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||South Africa|
|Removed Location Countries|
|NCT Number ICMJE||NCT01933477|
|Other Study ID Numbers ICMJE||Acct#5-30539|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Associate Professor Landon Myer, University of Cape Town|
|Study Sponsor ICMJE||University of Cape Town|
|Collaborators ICMJE||Columbia University|
|Information Provided By||University of Cape Town|
|Verification Date||July 2016|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP